NASDAQ:RGC Regencell Bioscience (RGC) Stock Price, News & Analysis $7.67 -2.14 (-21.81%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$7.71 +0.04 (+0.52%) As of 10/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Regencell Bioscience Stock (NASDAQ:RGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regencell Bioscience alerts:Sign Up Key Stats Today's Range$7.55▼$9.8250-Day Range$5.29▼$10.8052-Week Range$4.51▼$69.00Volume473,840 shsAverage Volume376,256 shsMarket Capitalization$3.80 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches. The company’s development activities center on proprietary herbal formulations and related treatment protocols. Regencell has described its work as an early-stage effort involving formulation development and clinical research, including studies intended to evaluate the safety and potential benefits of its candidates for individuals with ADHD and ASD. Its products remain subject to applicable research, regulatory and clinical-development requirements. Regencell was established in 2014 and is headquartered in Hong Kong. The company is led by Yat-Gai Au, who serves as chief executive officer and chairman. Regencell’s shares trade on the Nasdaq Capital Market under the symbol RGC.AI Generated. May Contain Errors. Read More Regencell Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreRGC MarketRank™: 0.482 of 5 starsRegencell Bioscience scored higher than 10% of companies evaluated by MarketBeat, and ranked 858th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRegencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRegencell Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Regencell Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRegencell Bioscience has a P/B Ratio of 255.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.14% of the float of Regencell Bioscience has been sold short.Short Interest Ratio / Days to CoverRegencell Bioscience has a short interest ratio ("days to cover") of 7.29.Change versus previous monthShort interest in Regencell Bioscience has recently decreased by 18.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegencell Bioscience does not currently pay a dividend.Dividend GrowthRegencell Bioscience does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentRegencell Bioscience has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Regencell Bioscience this week, compared to 4 articles on an average week.Search Interest3 people have searched for RGC on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regencell Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Regencell Bioscience is held by insiders.Percentage Held by Institutions0.13% of the stock of Regencell Bioscience is held by institutions.Read more about Regencell Bioscience's insider trading history. Receive RGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regencell Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGC Stock News HeadlinesRGC - Regencell Bioscience Holdings LimitedOctober 20, 2026 | seekingalpha.comHow Investors Are Reacting To Regencell Bioscience Holdings (RGC) Wider Full Year LossOctober 17, 2026 | finance.yahoo.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 24 at 1:00 AM | Brownstone Research (Ad)Is Regencell Bioscience Holdings (RGC) Fully Priced After Its Annual Loss Deepened?October 8, 2026 | finance.yahoo.comRegencell Bioscience: I Got It Wrong (Rating Downgrade)September 23, 2026 | seekingalpha.comRGC Resources: More Likely To Appeal More To Income-Focused InvestorsAugust 18, 2026 | seekingalpha.comRegencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-KJuly 3, 2026 | theglobeandmail.comRegencell Bioscience surges on apparent short squeezeJuly 1, 2026 | msn.comSee More Headlines RGC Stock Analysis - Frequently Asked Questions How have RGC shares performed this year? Regencell Bioscience's stock was trading at $21.00 on January 1st, 2026. Since then, RGC shares have decreased by 63.5% and is now trading at $7.67. How were Regencell Bioscience's earnings last quarter? Regencell Bioscience Holdings Limited (NASDAQ:RGC) released its quarterly earnings data on Wednesday, October, 7th. The company reported ($0.01) EPS for the quarter. When did Regencell Bioscience's stock split? Regencell Bioscience's stock split before market open on Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly created shares were payable to shareholders after the closing bell on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split. When did Regencell Bioscience IPO? Regencell Bioscience (RGC) raised $22 million in an IPO on Wednesday, July 14th 2021. The company issued 2,300,000 shares at a price of $8.50-$10.50 per share. How do I buy shares of Regencell Bioscience? Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regencell Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regencell Bioscience investors own include Coinbase Global (COIN), IREN (IREN), Lam Research (LRCX), Intuitive Machines (LUNR), Micron Technology (MU), Palantir Technologies (PLTR) and Archer Aviation (ACHR). Company Calendar Last Earnings10/07/2026Today10/24/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RGC Previous SymbolNASDAQ:RGC CIK1829667 Webregencellbioscience.com Phone852 2155 0823Fax852-2155-0853Employees10Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.77 Quick Ratio10.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book255.67Miscellaneous Outstanding Shares495,884,000Free Float485,966,000Market Cap$3.80 billion OptionableOptionable Beta1.18 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:RGC) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
